BIIB Biogen Inc. - Common Stock

NAS · US · Healthcare · Drug Manufacturers - General · biogen.com

218.26USD-0.74%Mkt Cap: 32.49B $P/E: 39.12Today

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple…

Industry Peers

Drug Manufacturers - General

Screen all

LLY

Eli Lilly and Company Common Stock

$1.02TUSDP/E 38.4

JNJ

Johnson & Johnson Common Stock

$617.01BUSDP/E 29.7

ABBV

AbbVie Inc. Common Stock

$464.43BUSDP/E 74.2

MRK

Merck & Company, Inc. Common Stock (new)

Novartis AG Common Stock

AstraZeneca PLC Ordinary Shares

Amgen Inc. - Common Stock

$217.90BUSDP/E 25.0

GILD

Gilead Sciences, Inc. - Common Stock

$179.47BUSD

NVO

Novo Nordisk A/S Common Stock

$164.79BUSDP/E 9.4

PFE

Pfizer, Inc. Common Stock

$158.45BUSDP/E 36.6

BMY

Bristol-Myers Squibb Company Common Stock

$124.91BUSDP/E 13.5

SNY

Sanofi - American Depositary Shares

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

Key Statistics

Company

Market Cap32.49B USD

Enterprise Value39.56B USD

Revenue (TTM)10.03B USD

Gross Profit7.49B USD

Net Income (TTM)1.29B USD

Revenue/Share68.19 USD

Last Price218.26 USD

Fiscal Year EndDec 2025

MR QuarterJun 2026

Employees7.5K

CountryUS

SectorHealthcare

IndustryDrug Manufacturers - General

ISIN—

Valuation

P/E (Trailing)39.12

P/E (Forward)13.30

PEG2.27

EV/EBITDA11.78

EV/Revenue3.94

P/S3.24

P/B1.72

EPS (TTM)5.63

EPS (Forward)16.54

52W Range

135.3987% of range230.49

52W High230.49 USD

52W Low135.39 USD

Profitability

Gross Margin75.69%

Oper. Margin25.06%

EBITDA Margin33.50%

Profit Margin13.07%

ROE7.08%

ROA4.39%

Growth

Revenue Growth3.40%

Earnings Growth-84.80%

Cash Flow & Leverage

Operating CF2.20B USD

CapEx (TTM)235.40M USD

FCF Margin12.63%

FCF Yield3.90%

Net Debt7.07B USD

Net Debt/EBITDA2.10

Balance Sheet

Debt/Equity0.36

Current Ratio1.86

Quick Ratio0.94

Book Value/Sh127.61 USD

Cash/Share8.70 USD

Dividends

Fwd Div Rate—

Trail. Div Rate0.00 USD

Div. Yield0.00%

5Y Avg Yield—

Payout Ratio0.00%

Ex-Div Date—

Pay Date—

Splits

Last Split3:1

Split DateJan 18, 2001

Analyst Consensus

Rating1.9 (Buy)

Strong BuyBuyHoldSellStr. Sell

Target (Mean)238.18 USD

Upside (mean)+9.1%

Target Range175.00 USD – 300.00 USD

175.00+9.1% to mean300.00

# Analysts31

Ownership

Shares Out.147.75M

Float147.22M

Insiders0.19%

Institutions99.51%

Short Interest

Short Ratio8.1d

Short % Float4.39%

Short % Out.3.94%

Shares Short5.82M

Short (prev mo.)5.19M

Technical

SMA 50215.29 (+1.4%)

SMA 200195.19 (+11.8%)

Beta0.17

S&P 52W Chg14.58%

Avg Vol (30d)944.80K

Avg Vol (10d)1.21M

Technical Indicators

RSI (14)50.4

MACD3.2158

MACD Signal3.6353

MACD Hist.-0.4195

BB Upper232.08 USD

BB Middle221.16 USD

BB Lower210.23 USD

BB Width9.88%

ATR (14)5.700 USD

Vol Ratio (20d)0.72x